Literature DB >> 9374919

The coagulation/fibrinolysis balance in systemic sclerosis: evidence for a haematological stress syndrome.

P R Ames1, S Lupoli, J Alves, T Atsumi, C Edwards, L Iannaccone, M A Khamashta, G R Hughes, V Brancaccio.   

Abstract

Systemic sclerosis (SSc) is a disease characterized by progressive microvascular occlusion and fibrosis resulting in irreversible organ damage, the pathogenesis of which is felt to be of vascular origin. To gain a comprehensive view of the coagulation/fibrinolytic balance in SSc, a number of haemostatic and fibrinolytic variables were measured in 26 SSc patients (11 limited, 15 diffuse) and in 22 control subjects. Of the coagulation activation markers, the mean plasma level of prothrombin fragment 1 + 2 (F1 + 2), but not of thrombin-antithrombin complexes (TAT), was higher in SSc patients than in controls (P < 0.001). Plasma levels of fibrin split product D-dimer (DD), fibrinogen (FNG) and von Willebrand factor (vWF) were higher amongst patients than controls (P < 0.001). vWF and FNG levels were positively correlated (P < 0.001). Mean levels of DD and vWF were more elevated in patients with diffuse than limited disease (P = 0.001 and P = 0.04, respectively). On the fibrinolytic side, defective tissue plasminogen activator (tPA) release (venous occlusion test, stimulated level < basal level) was noted in 46% (12/26) of SSc patients, but only in 4% (1/22) of controls. Patients had higher mean levels of tPA inhibitor (PAI) than controls (P < 0.001), levels being more elevated amongst patients with diffuse than limited disease (P = 0.01). An abnormally high lipoprotein (a) [Lp(a)] level was found in 9% (2/20) of control subjects, but in 30% (8/26) of SSc patients (P = 0.04) where it clustered with fibrinolytic defects. Altogether, these data suggest that patients with SSc are in a hypercoagulable state characterized by elevated plasma levels of FNG and vWF, by a dual hypofibrinolytic pattern (defective tPA release and elevated PAI), and by increased thrombin generation with enhanced fibrin formation. Higher levels of vWF, DD and PAI in patients with diffuse disease are consistent with more extensive (micro)vascular involvement, although no causal relationship can be inferred. The lack of a parallel increase of TAT with F1 + 2, in the presence of normal levels of antithrombin III (ATIII), indirectly suggests an impairment of the heparan sulphate-ATIII system which would favour thrombin generation. Since thrombin may act as a mitogen for fibroblasts, may upregulate vWF, PAI and endothelin production by endothelial cells, and may promote fibrin deposition on the vessel wall leading to worsening of microvascular occlusions, limitation of thrombin generation, besides fibrinolytic enhancement, could represent a possible coadjuvant interventional strategy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9374919     DOI: 10.1093/rheumatology/36.10.1045

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  22 in total

1.  Plasminogen activator inhibitor-1 as a link between pathological fibrinolysis and arthritis of Behçet's disease.

Authors:  M Akif Oztürk; Ihsan Ertenli; Sedat Kiraz; Ibrahim C Haznedaroğlu; Ismail Celik; Serafettin Kirazli; Meral Calgüneri
Journal:  Rheumatol Int       Date:  2003-05-15       Impact factor: 2.631

Review 2.  The pathogenesis, diagnosis and treatment of Raynaud phenomenon.

Authors:  Ariane L Herrick
Journal:  Nat Rev Rheumatol       Date:  2012-07-10       Impact factor: 20.543

3.  Systemic sclerosis following oral contraception.

Authors:  Lorenzo Beretta; Monica Caronni; Raffaella Scorza
Journal:  Clin Rheumatol       Date:  2004-07-14       Impact factor: 2.980

4.  Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot study.

Authors:  S Furukawa; S Yasuda; O Amengual; T Horita; T Atsumi; T Koike
Journal:  Ann Rheum Dis       Date:  2006-08       Impact factor: 19.103

Review 5.  New lines in therapy of Raynaud's phenomenon.

Authors:  Sevdalina Nikolova Lambova; Ulf Müller-Ladner
Journal:  Rheumatol Int       Date:  2008-11-27       Impact factor: 2.631

6.  Biochemical and morphological alterations in lungs induced by experimental inhibition of fibrinolytic activity.

Authors:  Izzet Hoşgör; Aysen Yarat; Nukhet Tüzüner; Faruk Alkan; Nesrin Emekli; Sarfraz Ahmad
Journal:  Mol Cell Biochem       Date:  2002-12       Impact factor: 3.396

Review 7.  Pathogenesis of Systemic Sclerosis.

Authors:  Debendra Pattanaik; Monica Brown; Bradley C Postlethwaite; Arnold E Postlethwaite
Journal:  Front Immunol       Date:  2015-06-08       Impact factor: 7.561

Review 8.  Microvascular involvement in systemic sclerosis and systemic lupus erythematosus.

Authors:  Didem Saygin; Kristin B Highland; Adriano R Tonelli
Journal:  Microcirculation       Date:  2019-04       Impact factor: 2.628

9.  Thrombotic complications after radial arterial line placement in systemic sclerosis: A case series.

Authors:  Julie J Paik; Ram Hirpara; Jennifer A Heller; Laura K Hummers; Fredrick M Wigley; Ami A Shah
Journal:  Semin Arthritis Rheum       Date:  2016-03-31       Impact factor: 5.532

10.  Raynaud's phenomenon.

Authors:  Ashraful Haque; Michael Hughes
Journal:  Clin Med (Lond)       Date:  2020-11       Impact factor: 2.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.